MALMÖ, Sweden– February 27, 2019
Following on from the successful launch of IL-2 and IL-6, two new interleukin cell lines, Svar Life Science now introduces another new cell line for use in the growth factor segment - iLite® Assay Ready Cells for G-CSF.
Granulocyte Colony-Stimulating Factor (G-CSF) is a type of growth factor that impacts the treatment and survival of patients and is used after chemotherapy to help white blood cells recover after treatment or before and after a stem cell transplant.
Designed to be highly specific, with simple and quick protocols, the iLite G-CSF Assay Ready Cells offer a large signal to noise ratio, high matrix tolerance and have high reproducibility.
The world market for G-CSFs is growing rapidly and a major force is the development of G-CSF biosimilars - due to the expiry of existing patents there is considerable interest from many companies to enter the marketplace. A number of biosimilar compounds of traditional G-CSF drugs are in clinical development and the iLite® Platform offers cell-based assays that enable the study and targeting of human growth factor proteins and their receptors. With the advantage of a biologically relevant assay system offering functional and quantitative read-outs, the iLite cell-based assay enables broad usage in applications such as functional screening, functional characterization, QC lot release (potency) assays and neutralizing antibody studies.
The assays are designed as Assay Ready Cells, giving you instant access to your assay. These cell-based assays can also be set up by our in-house GLP and GCP compliant laboratory Wieslab, offering bioanalytical services within (PK/PD), immunogenicity (ADA/NAb) and potency.
“We are delighted to announce several new cell lines during 2019 within our key focus areas. These additions to our cell-based portfolio will support extensions of use for already established products and reflect our continuing investment in the iLite cell-based solution platform” says Therese Segerstein, Product Manager Cell-based Solutions.
Learn more about "Colony Stimulating Factors - their unique biological roles and therapeutic benefits" in our blog post.
MALMÖ, Sweden– February 27, 2019
Following on from the successful launch of IL-2 and IL-6, two new interleukin cell lines, Svar Life Science now introduces another new cell line for use in the growth factor segment - iLite® Assay Ready Cells for G-CSF.
Granulocyte Colony-Stimulating Factor (G-CSF) is a type of growth factor that impacts the treatment and survival of patients and is used after chemotherapy to help white blood cells recover after treatment or before and after a stem cell transplant.
Designed to be highly specific, with simple and quick protocols, the iLite G-CSF Assay Ready Cells offer a large signal to noise ratio, high matrix tolerance and have high reproducibility.
The world market for G-CSFs is growing rapidly and a major force is the development of G-CSF biosimilars - due to the expiry of existing patents there is considerable interest from many companies to enter the marketplace. A number of biosimilar compounds of traditional G-CSF drugs are in clinical development and the iLite® Platform offers cell-based assays that enable the study and targeting of human growth factor proteins and their receptors. With the advantage of a biologically relevant assay system offering functional and quantitative read-outs, the iLite cell-based assay enables broad usage in applications such as functional screening, functional characterization, QC lot release (potency) assays and neutralizing antibody studies.
The assays are designed as Assay Ready Cells, giving you instant access to your assay. These cell-based assays can also be set up by our in-house GLP and GCP compliant laboratory Wieslab, offering bioanalytical services within (PK/PD), immunogenicity (ADA/NAb) and potency.
“We are delighted to announce several new cell lines during 2019 within our key focus areas. These additions to our cell-based portfolio will support extensions of use for already established products and reflect our continuing investment in the iLite cell-based solution platform” says Therese Segerstein, Product Manager Cell-based Solutions.
Learn more about "Colony Stimulating Factors - their unique biological roles and therapeutic benefits" in our blog post.